Amp Fund Performance since Jan 2017

About AMP 

At Amp, we research biopharma companies primarily with valuations between $200M and $5B, who have upcoming catalyst events in the next 12 months, and invest in some of these companies in the Amp Hedge Fund, LP, as well as a series of hypothetical funds where we test different strategies. The performance above is based on our hypothetical Amp 1.0 fund from January 1, 2017 to July 1, 2018, and since then based on our real hedge fund (Amp Fund, LP). 

To learn more about Amp, see the About Amp page.


Amp Biopharma Investment Blog

Our free blog features periodic and shortened company and investment updates.  Amp Core members get all updates and our full quarterly and company reports. Learn More


To view only our blog posts for biopharma investors that are a collaboration between Amp and our Double Helix Law IP team, CLICK HERE


Contact Us

Interested and want to learn more? Send us a note below. 

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon